WallStSmart

Accenture plc (ACN)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Accenture plc generates 187% more annual revenue ($72.11B vs $25.12B). SYK leads profitability with a 12.9% profit margin vs 10.6%. ACN appears more attractively valued with a PEG of 1.58. SYK earns a higher WallStSmart Score of 65/100 (C+).

ACN

Buy

60

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 7.3Quality: 5.3
Piotroski: 3/9Altman Z: 2.79

SYK

Buy

65

out of 100

Grade: C+

Growth: 8.0Profit: 7.5Value: 9.3Quality: 7.0
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ACNSignificantly Overvalued (-26.5%)

Margin of Safety

-26.5%

Fair Value

$153.01

Current Price

$193.54

$40.53 premium

UndervaluedFair: $153.01Overvalued
SYKUndervalued (+16.3%)

Margin of Safety

+16.3%

Fair Value

$392.65

Current Price

$328.51

$64.14 discount

UndervaluedFair: $392.65Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACN4 strengths · Avg: 8.5/10
Market CapQuality
$124.02B9/10

Large-cap with strong market position

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

P/E RatioValuation
16.8x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$3.67B8/10

Generating 3.7B in free cash flow

SYK4 strengths · Avg: 8.8/10
EPS GrowthGrowth
55.9%10/10

Earnings expanding 55.9% YoY

Market CapQuality
$128.46B9/10

Large-cap with strong market position

Operating MarginProfitability
27.2%8/10

Strong operational efficiency at 27.2%

Free Cash FlowQuality
$1.88B8/10

Generating 1.9B in free cash flow

Areas to Watch

ACN3 concerns · Avg: 3.7/10
PEG RatioValuation
1.584/10

Expensive relative to growth rate

EPS GrowthGrowth
3.8%4/10

3.8% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SYK3 concerns · Avg: 3.0/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
40.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ACN

The strongest argument for ACN centers on Market Cap, Return on Equity, P/E Ratio.

Bull Case : SYK

The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.

Bear Case : ACN

The primary concerns for ACN are PEG Ratio, EPS Growth, Piotroski F-Score.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 40.0x leaves little room for execution misses.

Key Dynamics to Monitor

ACN carries more volatility with a beta of 1.25 — expect wider price swings.

SYK is growing revenue faster at 11.4% — sustainability is the question.

ACN generates stronger free cash flow (3.7B), providing more financial flexibility.

Monitor INFORMATION TECHNOLOGY SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (65/100 vs 60/100) and 11.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Accenture plc

TECHNOLOGY · INFORMATION TECHNOLOGY SERVICES · USA

Accenture plc is an Irish-domiciled multinational company that provides consulting and processing services. It has been incorporated in Dublin, Ireland since 2009.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?